Crenezumab: Ph Ib data

Data from 52 patients with mild to moderate AD in a double-blind, dose-escalation, placebo-controlled, U.S. Phase Ib trial showed that 30, 45 and 60 mg/kg doses of IV crenezumab once every 4 weeks for...